CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)
0.6050
+0.0050 (0.83%)
Aug 21, 2026, 4:08 PM HKT
HKG:0775 Revenue
CK Life Sciences Int'l., (Holdings) had revenue of 2.72B HKD in the half year ending June 30, 2026, with 3.03% growth. This brings the company's revenue in the last twelve months to 5.52B, up 0.50% year-over-year. In the year 2025, CK Life Sciences Int'l., (Holdings) had annual revenue of 5.41B, down -2.04%.
Revenue (ttm)
5.52B
Revenue Growth
+0.50%
P/S Ratio
1.05
Revenue / Employee
2.87M
Employees
1,920
Market Cap
5.81B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.41B | -112.45M | -2.04% |
| Dec 31, 2024 | 5.52B | 199.94M | 3.76% |
| Dec 31, 2023 | 5.32B | 47.14M | 0.89% |
| Dec 31, 2022 | 5.28B | -126.72M | -2.35% |
| Dec 31, 2021 | 5.40B | 459.77M | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.73B |
| Qyuns Therapeutics | 1.18B |
| Lepu Biopharma | 1.14B |
| Ocumension Therapeutics | 895.09M |
| Abbisko Cayman | 681.17M |
| Mirxes Holding Company | 166.32M |
| Jacobio Pharmaceuticals Group | 59.56M |
| Shanghai Bao Pharmaceuticals | 54.70M |
CK Life Sciences Int'l., (Holdings) News
- 5 months ago - Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline - South China Morning Post
- 11 months ago - CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs - South China Morning Post
- 11 months ago - TransCode Acquires Polynoma From CK Life Sciences - Nasdaq
- 2 years ago - CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings - South China Morning Post